|
|
Time |
Source |
|
Announcement
|
|
| 13 Nov 2018 |
9:28 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London |
| 11 Nov 2018 |
4:45 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients |
| 05 Nov 2018 |
6:00 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms |
| 02 Nov 2018 |
10:00 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs |
| |
9:15 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology |
| 31 Oct 2018 |
4:30 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz) |
| 29 Oct 2018 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH |
| 27 Oct 2018 |
3:08 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD |
| 26 Oct 2018 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis |
| 23 Oct 2018 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Alcon to develop SMART Suite digital health platform for cataract surgery |
| 22 Oct 2018 |
11:30 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig® where other treatments have failed |
| |
8:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma |
| 20 Oct 2018 |
3:30 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone |
| 19 Oct 2018 |
3:00 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC |
| |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden |
| 18 Oct 2018 |
6:02 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms |
| |
6:00 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth |
| 16 Oct 2018 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis |
| 11 Oct 2018 |
9:35 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access |
| 10 Oct 2018 |
9:30 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis |
| |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden |
| 09 Oct 2018 |
9:30 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study |
| 08 Oct 2018 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients |
| 04 Oct 2018 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges |
| 03 Oct 2018 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals |
| 22 Sep 2018 |
1:41 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness |
| |
1:36 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD |
| 21 Sep 2018 |
12:27 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim |
| |
12:25 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe |
| |
12:24 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis announces positive CHMP opinion for one-time gene therapy Luxturna® to treat children and adults with rare inherited retinal disease |
| 17 Sep 2018 |
9:30 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime |
| |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Launch of Alcon Experience Academy Reinforces Commitment to Training and Education for Eye Care Professionals |
| 13 Sep 2018 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx® in daily life for psoriasis patients |
| 12 Sep 2018 |
10:00 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS |
| |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis survey shows psoriasis patients want treatment effect beyond clear skin |
| 11 Sep 2018 |
6:00 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis |
| 06 Sep 2018 |
3:30 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo |
| 29 Aug 2018 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
European Commission approves Novartis combination therapy Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600 mutation-positive melanoma |
| |
6:00 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma |
| 27 Aug 2018 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel) |
| 25 Aug 2018 |
10:00 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode |
| 23 Aug 2018 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation |
| 14 Aug 2018 |
6:00 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer |
| 30 Jul 2018 |
9:30 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention |
| 27 Jul 2018 |
1:53 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab) |
| |
1:23 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma |
| 23 Jul 2018 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke |
| 19 Jul 2018 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis |
| 18 Jul 2018 |
4:30 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women |
| |
6:00 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company |
| 29 Jun 2018 |
1:10 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe |
| |
6:00 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn |
| 28 Jun 2018 |
9:30 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine |
| 27 Jun 2018 |
9:30 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month |
| 26 Jun 2018 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin |
| 18 Jun 2018 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis International AG: Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery |
| 16 Jun 2018 |
10:30 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL |
| 15 Jun 2018 |
7:40 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life |
| |
7:35 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer |
| |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis |